VOLT 01 Reformulated Zoledronic Acid Targeted to be

VOLT 01 Reformulated Zoledronic Acid Targeted to be the first Disease. Modifying Drug in Osteoarthritis

ØVOLT 01, a reformulated zoledronic acid, has demonstrated superior efficacy and safety in patients with knee osteoarthritis vs Novartis’ Reclast® ØVOLT 01 has advanced to phase III in Australia and is targeting a global placebo-controlled phase III trial in 1 H 2016. ØVOLT 01 has broad patent protection in the U. S. and in International markets. Executive Summary ØLevolta reformulates approved products to enhance their customer value, such as efficacy, safety and convenience.

+ VOLT 01 = Current Focus Levolta is currently focused on the development of its lead product, VOLT 01, which will be the first approved therapy that treats osteoarthritis disease.

ACR Poster Presentation Post-dose Reclast® 9/16 (56%) 0 -10 mm VOLT 01 2/16 (13%) 0 -35 mm EFFICACY: VOLT 01 was statistically significantly superior to ZA (measured by VAS) with p<0. 05*. SAFETY: VOLT 01 was superior to ZA in safety (measured by PDS). SUSTAINED EFFECT: Patients in these cohorts were followed for 6 months with a significant reduction in pain still being reported. DISEASE MODIFICATION: The sustained effect suggests that disease is being modified, as was also suggested by the ZAP** study. • Statistical analysis was done by an independent contractor (Percept Pharma Services, NJ). • A phase 2 randomized controlled trial of ZA in OA of knee in Australia (ZAP study, Zoledronic Acid for Knee Pain) showed efficacy at six months of ZA in decreasing bone marrow lesions in OA by MRI. Superior Phase II data Cohort Change in Mean Visual in Bone Analogue Score Syndrome Marrow (pain measurement) (Main Side effect) Density

Knee OA $2. 7 B $0. 5 B $1. 5 B Rheumatoid arthritis $4. 5 B $14 B Osteoarthritis Psoriatic arthritis Ankylosing spondylitis The market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7. 2% between 2010 and 2018 to $38 billion. Total Addressable Arthritis Market Estimated Global Sales in 2010 = $20. 6 B

VOLT 01 (zoledronic acid) There are no approved therapies that treat osteoarthritis disease, only the associated signs and symptoms. VOLT 01 is the only DMAOD currently in development. Competition Indirect competition may exist from pain and anti-inflammatory mediations, as well as surgeons with practice economic concerns.

Phase III trial in Australia (cost effective trial with Menzies Group provides differentiation vs Reclast. Results will drive global reimbursement). 2 Enter Phase III trial in Russia 2016 (will serve as a supportive trial for FDA / EMA approval. Independent regulatory body and cost efficiencies make Russia an attractive space). Leverage interim analysis data from AU into FDA / EMA meeting Begin Global Phase III trial of VOLT 01 3 2016 4 File New Drug Application (NDA) with 2016 Therapeutic Goods Administration in Australia 5 File NDA with FDA, EMA & Ministry of Health (RUS) 2017 6 Approvals in AU, NZ & some Asia Pacific countries 2017 7 Approvals in USA & Russia 2018 8 Approvals in Europe & rest of world 7 VOLT 01 Regulatory Path 2014 -15 1

• Pharmacoeconomic benefit • Enhanced Patient Compliance • Superior safety profile Advantages of VOLT 01 • First line in treatment of osteoarthritis

United States Patent # 8, 859, 530 issued on 10/14/14 United States Patent # 9, 012, 432 issued on 04/21/15 Much broader claims …. Treatment of osteoarthritis with ZA and any steroid (not just prednisolone), but to any mode of administration (not just IV), and not just a single infusion. The application also includes various composition claims. 03/11/15 - Patent Cooperation Treaty Application No: PCT/US 14/22169 International Preliminary Examination Report (“IPRP”) concluded that all of the pending claims have been indicated as being novel, inventive, and having industrial applicability. Intellectual Property Claims methods for treating OA by intravenously administering a combination of Zoledronic acid and steroids in a single infusion. Covers a method for providing long-term relief to OA.

• Levolta is interested in global, regional and local partnering opportunities. • VOLT 01 is projected to be commercialized in 3 years. Partnering Opportunity • Levolta is seeking a partner for development, sales and registration.

Richard Becker, CEO Levolta Pharmaceuticals Rbecker@levoltapharma. com 848. 702. 0682 Contact Information After reviewing this Presentation Deck please feel free to contact Mr. Richard Becker with any questions you may have.